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Tbjective: Recent evidence suggests that the effects of mesenchymal progenitor cell
ransplantation into the infarcted myocardium might be mediated by local paracrine
ngiogenesis. We compared the effects of mesenchymal progenitor cell transplan-
ation versus those of a primarily angiogenic cell, the endothelial progenitor cell, in
rat model of myocardial infarction.
ethods: Twenty-one days after left anterior descending artery ligation, rats were
njected in their infarcted anterior myocardium with 1  106 mesenchymal progen-
tor cells, 1  106 endothelial progenitor cells, 5  105 mesenchymal progenitor
ells plus 5  105 endothelial progenitor cells, or phosphate-buffered saline (n 
-8 per group). Echocardiography was performed before injection and 4 weeks later,
fter which rats were killed and immunohistochemical analyses performed.
esults: Connexin43 density was greater in cell-treated groups compared with that
een in the phosphate-buffered saline group (by 91.6%  15.2%, P  .001), with
o observed difference between cell-treated groups (P  .3). Endothelial progenitor
ell treatment increased arteriolar density within the infarct border zone (by 297%,
05%, and 101% vs phosphate-buffered saline, mesenchymal progenitor cell, and
esenchymal progenitor cell/endothelial progenitor cell treatment, respectively;
 .01). Postoperative left ventricular ejection fraction (endothelial progenitor cell:
8.3%  9.8% vs mesenchymal progenitor cell/endothelial progenitor cell: 55.0% 
1.1%, mesenchymal progenitor cell: 53.0%  6.0%, and phosphate-buffered
aline: 49.6%  9.5%) and fractional shortening (endothelial progenitor cell: 32.4%
.1% vs mesenchymal progenitor cell: 22.5%  5.4% and phosphate-buffered
aline: 21.3%  5.3%) were greater in endothelial progenitor cell–treated rats
ersus those receiving other treatments (all P  .05). Only endothelial progenitor
ells prevented further contractile deterioration compared with baseline values (P
8), whereas other groups had continued loss of function after treatment.
onclusion: Compared with the use of mesenchymal progenitor cells, cell trans-
lantation with endothelial progenitor cells after myocardial infarction resulted in
etter neovascularization and contractility. This suggests that angiogenesis is an
mportant mechanism in attenuating the progression of left ventricular dysfunction
fter myocardial infarction.
ell-based myocardial regenerative therapies aim at safely using bone
marrow–, blood-, or tissue-derived progenitor cells to restore perfusion and
function to chronically ischemic, stunned, hibernating, or scarred myocar-
ial areas and at improving patient quality of life and survival beyond the effects of
ther available therapeutic modalities. To date, this remains an elusive goal.
Under selected experimental conditions, bone marrow–derived mesenchymal
rogenitor cells (MPCs) have been reported to generate cardiomyocytes1,2 and
he Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 5 1249
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1
ETherefore constitute a candidate for cell-based therapy. In
yocardial infarction (MI) models, transplantation of
PCs into the infarct region has been shown to improve left
entricular ejection fraction (LVEF) and cardiac function.3
owever, studies on large animals and early clinical inves-
igations of MPC therapy after MI have showed only mod-
st regional contractile improvements with little or no
lobal recovery, and underlying mechanisms remain un-
lear.4-6 Recent evidence suggests that MPCs do not result
n the formation of functional syncytia and that their effects
n post-MI scarring might be mediated more by local para-
rine angiogenesis than by cardiomyocyte differentiation.3,7
ence, angiogenesis (the formation of new blood vessels)
ight constitute an important mechanism of functional im-
rovement not only among modalities that specifically aim
t angiogenesis (ie, for the treatment of myocardial ischemia
n the presence of viable heart muscle), but also among
odalities aiming at myogenesis to improve cardiac func-
ion after an MI (ie, for the treatment of heart failure in the
resence of nonviable myocardium).8,9
If angiogenesis is the underlying mechanism for im-
roved cardiac function after MPC treatment after MI,
hen transplantation of angiogenic/vasculogenic progen-
tors might constitute another cell-based approach to
chieve post-MI recovery. Among the potential sources of
tem/progenitor cells, circulating endothelial progenitor
ells (EPCs) and their derivatives have important angio-
enic properties.10 EPCs can be recruited from the blood to
ites of angiogenesis, differentiate into endothelial cells, and
roliferate to form new vasculature,11 and might provide
itogenic factors for mature endothelial cells.12 Animal
odels have demonstrated a role for EPCs in enhancing
ascularization in the infarcted, as well as in the ischemic,
eart.13,14
Two clinical trials have examined the effects of intra-
oronary marrow–derived cells versus EPC injections for
he treatment of MI, without any observed difference in
ecovery between the 2 cell-treated groups.5,15 However, no
tudy to date has compared MPCs versus EPCs by using
ntramyocardial cell delivery, which is more targeted and
Abbreviations and Acronyms
EPC  endothelial progenitor cell
FS  fractional shortening
HPS  hematoxylin-phloxine-saffron
LV  left ventricular
LVEF left ventricular ejection fraction
LVID  left ventricular internal dimension
MI myocardial infarction
MPC mesenchymal progenitor cell
PBS  phosphate-buffered salineffective than intracoronary injection.16 Furthermore, no t
250 The Journal of Thoracic and Cardiovascular Surgery ● Novtudy has directly compared the underlying mechanisms of
ecovery and regeneration after cell therapy by using these
widely used cell populations. Therefore we compared and
ombined the use of MPCs and circulatory EPCs for cell-
ased therapy in a rat MI model and examined the hypoth-
sis that the EPC, because of its high angiogenicity,10,11
ight elicit an equal or better therapeutic response than the
PC. The data presented herein suggest that focusing on
he transplantation of primarily vasculogenic cells, such as
he EPC, might be an equally viable or even superior
ell-based approach for the treatment of post-MI cardiac
ysfunction.
aterials and Methods
ell Isolation and Culture
PCs and EPCs were isolated from healthy donor syngeneic
prague–Dawley rats (Charles River, Wilmington, Mass) weigh-
ng 200 to 250 g that did not undergo MI induction or any other
anipulation. For EPCs, blood was collected from the aortas of
nesthetized rats (2% isoflurane). Total peripheral blood mononu-
lear cells were isolated and cultured, as described previously.17
riefly, cultures were supplemented with endothelial basal me-
ium with EGM-2-MV-SingleQuots (Clonetics, Guelph, Canada),
nd day 4 adherent cells represented the EPC population. Charac-
eristic of EPCs, these cells stained positive for 1,1=-dioctadecyl-
,3,3=,3=-tetramethylindocarbocyanine–labeled acetylated low-
ensity lipoprotein uptake and fluorescein isothiocyanate–labeled
lex europaeus agglutinin 1 binding (not shown). For MPCs,
ibias and femurs were dissected from rats after death. Bone
arrow was extruded from rat tibias and femurs by using a needle
nd syringe and flushing with phosphate-buffered saline (PBS).
ells were isolated from the bone marrow extract by means of
ollagenase treatment (250 L/mL; Sigma, Oakville, Canada) and
hen cultured at 1.3 105 cells/cm2 until confluent (approximately
4 days) in Dulbecco’s modified Eagle’s medium (Sigma) supple-
ented with 10% fetal bovine serum, L-glutamine (2 mmol/L),
enicillin (100 U/mL), and streptomycin (100 mg/mL). Nonadher-
nt erythroid progenitor cells were removed with each medium
hange, yielding a population of adherent MPCs that characteris-
ically expressed the antigens CD29 and CD44 but were negative
or the hemopoietic cell marker CD45.18 Before transplantation,
PCs or EPCs for single cell-type injections were labeled with
=,6-diamidino-2=-phenylindole (Sigma); in the case of dual cell-
ype injections, MPCs were labeled as above, and EPCs were
abeled with carboxyfluorescein diacetate (Molecular Probes, Eu-
ene, Ore), according to the manufacturer’s protocol.
nimal Model
nimal procedures (Figure 1) were performed with the approval of
he University of Ottawa Animal Care Committee in accordance
ith the National Institute of Health’s “Guide for the care and use
f laboratory animals.” Syngeneic Sprague–Dawley rats (200-250 g)
ere used for the infarction and cell transplantation model. Left
oronary artery ligation procedures were performed by Charles
iver surgical services, and animals were shipped after recovery.
Baseline echocardiography was performed 14 days after liga-
ion (as below). Animals were then randomized to receive injec-
ember 2007
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ETions of cells or PBS (controls) 7 days later. The lack of difference
n baseline ejection fraction and fractional shortening (FS) values
etween groups confirmed an equivalent degree of infarction be-
ween treatment groups. Mechanical ventilation was established in
nesthetized rats (isoflurane), and the heart was exposed through a
eft thoracotomy. By using a 27-gauge needle, 5 equivolumetric
ntramyocardial injections (200 L in total) were performed in a
tandardized fashion, one at each border and one in the middle of
he dyskinetic and discolored anterior myocardial area represent-
ng the infarction. Randomized animals were injected with one of
he following in PBS: (1) 1  106 MPCs; (2) 1  106 EPCs; (3)
 105 MPCs plus 5  105 EPCs; or (4) PBS only.
chocardiographic Analysis
aseline (14 days after MI and 7 days before cell transplantation)
nd posttreatment (after 28 days) transthoracic echocardiographic
nalysis of rat hearts were performed by using a small animal–
ompatible analog echocardiography system (Philips, Markham,
anada). Rats were anesthetized (isoflurane) in the supine posi-
ion, and their chests were shaved. The heart was imaged in a
hort-axis view of the left ventricle at the level of the papillary
uscle. End-diastolic and end-systolic left ventricular (LV) inter-
al dimension (LVID) measurements were taken. LVEF, FS, and
he end-diastolic and end-systolic LV volume indices (in microli-
ers per gram of body weight) were calculated. Measurements were
nterpreted by 2 blinded echocardiographers and averaged. Re-
orted values have been normalized to baseline values for all
reatment groups.
istologic Assessment
fter death, hearts were immediately dissected and fixed with 4%
araformaldehyde. Tissue was then stored in 10% neutral-buffered
ormalin, serially sectioned, and paraffin embedded. Slides were
repared by using 4-m serial sections at different levels. Sections
ere stained with hematoxylin-phloxine-saffron (HPS) stain- S
The Journal of Thoracicng. For determining infarct size and length and for measuring
he anterior and posterior LV wall thickness, computer-assisted
lanimetry was performed. Infarct size was calculated as the
nfarcted area divided by the total LV area. The inflammatory
ell reaction was estimated by grading the number of leukocytes
er HPS-stained tissue section (0, none; 1, low; 3, medium; 5,
evere). Vascular density in the scar and border zone was
alculated as the number of arterioles per square millimeter by
sing HPS-stained slides and slides stained for -smooth mus-
le actin (-SMA; see below). Counts were determined from 6
andom microscopic fields (at a minimum of 3 tissue levels) per
ample in a blinded fashion.
Cardiac troponin T, -SMA, and connexin43 were localized by
eans of immunohistochemical staining with anti-cardiac troponin
(1:50; Santa Cruz Biotechnology, Santa Cruz, Calif), anti--
MA (1:400; Chemicon, Temecula, Calif), and anti-connexin43
1:200; Chemicon) antibodies, according to the manufacturer’s
rotocol. Differentiation of transplanted cells into cardiomyocytes
as assessed on the basis of the expression of cardiac troponin
. The density of -SMA– expressing myofibroblasts was cal-
ulated and reported as the area of -SMA–positive staining/
nfarct area (as a percentage), while excluding characteristic
-SMA–positive staining of arteriolar vessel walls. The -SMA
taining also identified smooth muscle cells in arterioles, which
ere distinguished from myofibroblasts by their distinctive
orphology. The densities of intercellular connexin43 staining
ere measured in infarct and peri-infarct area myocytes and
eported as the number of intercalated discs that contained
onnexin43/myocyte. All counts were determined from 6 ran-
om microscopic fields (at a minimum of 3 tissue levels) per
ample in a blinded fashion.
tatistics
alues are expressed as means  standard deviation of the mean.
Figure 1. Experimental design. A, The
left descending coronary artery was
ligated. B, Echocardiographic analysis
was performed 14 days after ligation.
C, At post–myocardial infarction day
21, cell transplantation was performed
into the infarcted region. D, Echocardi-
ography was performed 1 month after
cell transplantation, and the experi-
ment was terminated.tatistical analyses were performed with Intercooled Stata 8 soft-
and Cardiovascular Surgery ● Volume 134, Number 5 1251
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1
ETare (StataCorp, College Station, Tex). Comparisons of continu-
us data between groups were performed with a 1-way analysis of
ariance adjusted for repeat measures, a 2-tailed Student t test, or
oth, using Bonferroni corrections as appropriate.
esults
hree (9%) of 32 rats died after coronary ligation and before
njection, and a further loss of 2 animals occurred after cell
reatment. These animals were excluded from the analyses.
he final sample sizes per treatment group were as follows:
1) MPCs (n  6); (2) EPCs (n  7); (3) MPCs/EPCs (n 
); and (4) PBS (n  6).
ngraftment and Differentiation of Transplanted Cells
fter 4 weeks, the majority of EPC and MPC engraftment
ccurred within the scar regions and border zone (Figure 2,
and B); however, some labeled cells were also observed
ithin the healthy myocardium. EPCs were observed to
ncorporate into the endothelial walls of blood vessels (Fig-
re 2, C), whereas MPCs were not. Only transplanted MPCs
ere found to express the cardiomyocyte marker troponin T
Figure 2, D); however, expression was observed only in 7
f 102 sections examined.
istologic Assessment of Infarcts
athologic assessment revealed no significant difference in
ransmurality or inflammation (P  .52 and .25, respec-
ively; data not shown) between the treatment groups. The
ize of the infarcted myocardium was similar between treat-
ents (Table 1). The EPC-treated group demonstrated re- s
252 The Journal of Thoracic and Cardiovascular Surgery ● Novuced infarct length and greater anterior/posterior wall
hickness ratio (Table 1). Less myofibroblasts (0.25% 
.11%) were observed in the EPC-treated group compared
ith the PBS-, MPC-, and MPC/EPC-treated groups (2.59%
.58%, 1.09%  0.32%, and 0.63%  0.17%, respectively;
igure 3). The potential for intercellular communication
etween cardiomyocytes was assessed on the basis of inter-
ardiomyocyte connexin43 density (Figure 4, A and B).
onnexin43 staining was greater in cell-treated groups com-
ared with that seen in the PBS-treated group (by 91.6% 
5.2%), but no difference was observed among cell groups
Figure 4, C).
EPC-treated hearts demonstrated greater vascular density
ithin the scar territory. EPC treatment alone resulted in
ignificantly greater arteriolar density within the infarct
23.3  13.1 arterioles/mm2) compared with PBS, MPC
lone, and MPC/EPC treatment (6.7  4.3, 9.9  4.6, and
2.1  5.3 arterioles/mm2, respectively). This represents
ncreases in arteriolar density of 248%, 135%, and 93%
fter EPC treatment versus PBS, MPC, and MPC/EPC
reatment. More notably, arteriole density was significantly
reater in the infarct border zone of EPC-treated hearts
62.3  15.5 arterioles/mm2) versus those undergoing PBS,
PC, and MPC/EPC treatment (15.7 3.6, 20.4 3.9, and
1.0  9.0 arterioles/mm2, respectively; Figure 5, A-D).
his represents increases in arteriolar density of 297%,
05%, and 101% after EPC treatment versus that after PBS,
PC, and MPC/EPC treatment. The results for vessel den-
Figure 2. Cell engraftment and differen-
tiation. Representative images of the
following are shown: A, 4=,6-diamidino-
2=-phenylindole (DAPI)–labeled nuclei
(blue) of mesenchymal progenitor cells
(MPCs) within the scar tissue; B, cotrans-
planted endothelial progenitor cells (EPCs;
green) and MPCs (blue) in the border
zone; C, evidence for endothelial differen-
tiation of engrafted DAPI-positive EPCs
(arrowheads) within vessels in the in-
farct; and D, evidence for cardiomyo-
cyte differentiation of engrafted DAPI-
positive MPCs (arrowheads) with
coexpression of cardiac troponin T (green).
Scale bar 250 m (A and B), 40 m (C),
and 30 m (D).ities are summarized in Figure 5, E.
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ETV Function
nimal heart rates were equal between groups (Table 1). As
n indication of reduced dilatation, only EPC-treated rats
ad both lower end-diastolic and end-systolic LV volume
ndices (normalized for body weight, Table 1) compared
ith PBS control animals. The baseline LVEF, FS, and
nd-systolic and end-diastolic LVIDs were not significantly
ifferent between treatment groups (Figure 6). Four weeks
fter transplantation, LVEF decreased significantly from
aseline in the PBS-treated (69.0%  11.7% to 49.6% 
.5%), MPC-treated (68.3%  18.9% to 53.0%  6.0%),
nd MPC/EPC-treated (69.4%  7.4% to 55.0%  11.1%;
igure 6, A) groups. In contrast, there was no significant
hange in LVEF for the EPC-treated group (66.4% 
7.6% to 68.3%  9.8%; Figure 6, A). Also, posttransplan-
ation LVEF was greater in EPC-treated hearts compared
ith those undergoing all other treatments (by 24.1%,
 .05). After 28 days, FS was significantly greater in the
PC-treated hearts (32.4%  5.1%) compared with values
n the other treatment groups (21.3%  5.4% and 22.6% 
.6% for PBS and MPC treatment, respectively; Figure 6,
). EPC treatment also prevented further changes in LVID
easurements, with significantly reduced postoperative
nd-diastolic (7.8  1.5 mm) and end-systolic (5.4  1.3
m) LVID observed in EPC-treated hearts compared with
hat seen in PBS-treated control hearts (10.1  1.4 mm and
.6  2.0 mm for end-diastolic LVID and end-systolic
VID, respectively; Figure 6, C and D).
iscussion
n this study, the vasculogenic, regenerative, and func-
ional effects of EPCs and MPCs were directly compared
n a rat MI model. It was demonstrated that (1) trans-
lantation of EPCs was associated with a significant
ncrease in vasculature within the MI and border zone,
2) EPCs but not MPCs were seen directly incorporating
ABLE 1. Histologic and echocardiographic infarct param
PBS
istology–planimetry
Infarcted area 0.37 0.08
Infarct Length (cm) 1.17 0.10
AWT/PWT 0.67  0.10
chocardiographic analysis†
Rat weight (g) 343 18
Heart rate (beats/min) 368 39
EDVI (L/g) 3.15 1.20
ESVI (L/g) 2.80 1.44
nfarct size is shown as the ratio of infarcted area to total left ventricular
hickness (AWT) to posterior wall thickness (PWT). End-diastolic (EDVI) a
eight. PBS, Phosphate-buffered saline; MPC, mesenchymal progenitor ce
reatment. †None of these parameters were significantly different at basento endothelial walls of blood vessels, and (3) further s
The Journal of Thoracicoss of LV function after transplantation was prevented in
he EPC-treated group only. This constitutes the first
omparative study to demonstrate better preservation of
yocardial function after MI using EPCs compared with
hat demonstrated using MPCs and to correlate this ob-
ervation with superior neovascularization.
An important role for EPCs in angiogenesis has previ-
usly been established,11 and animal studies have demon-
trated enhanced neovascularization with use of these cells
n ischemic models.12,13 In this study, increased formation
f capillaries was seen in infarcted myocardium when using
PCs compared with MPCs (data not shown). More impor-
antly, EPC treatment resulted in greater numbers of fully
ormed arterioles in the border zone and infarct territories.
uch vessels are presumably longer lasting than are the
eaky small capillaries that result from local paracrine ef-
ects and inflammation.19 A lesser response was observed
or the combined MPC/EPC treatment, possibly because of
dose effect, as demonstrated previously for the assessment
f angiogenic therapy.20 Overall, it is possible that EPCs
ight regenerate a more functional vasculature in the in-
arcted heart. This might be particularly important in the
order zone, where stunned or hibernating myocardium
which is viable but with suboptimal function) could be
ecovered with the help of a restored blood supply, thus
inimizing the degenerative process.21,22
Echocardiography was used to assess progression of LV
ysfunction after cell transplantation with the various cell
ypes. Contrary to the other treatment groups, when EPCs
ere transplanted alone, further loss in myocardial function
LVEF and FS) was prevented. These data suggest that
nhanced angiogenesis after EPC injection might be asso-
iated with the prevention of further loss of myocardium
eg, stunned or hibernating), with the attenuation of adverse
V remodeling, or both. Mechanistically corroborating this
at 28 days after treatment
MPC EPC MPC/EPC
.36  0.05 0.35 0.10 0.37  0.07
.09  0.31 0.82 0.15* 1.12  0.26
.76  0.15 0.87 0.13* 0.71  0.14
345  35 340 19 341  22
392  43 377 12 365  29
.12  0.62 1.56 0.80* 2.77  1.57
.95  0.36* 0.53 0.38* 1.38  1.00
. Left ventricular wall thickness is calculated as the ratio of anterior wall
nd-systolic (ESVI) left ventricular volume indices are normalized to body
C, endothelial progenitor cell. *P  .05 versus phosphate-buffered salineeters
0
1
0
2
0
area
nd e
ll; EPtatement is the observation that after 4 weeks (1) the level
and Cardiovascular Surgery ● Volume 134, Number 5 1253
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1
ETf myofibroblasts, suggestive of adverse remodeling and
car formation,23 was lower in EPC-treated hearts compared
ith in hearts undergoing other treatments, and (2) only
PC treatment reduced infarct length and significantly pre-
ented LV wall thinning and dilatation compared with that
een in PBS-injected control hearts. This is a novel finding
n that previous trials comparing marrow-derived versus
irculatory progenitor cells have been unable to demonstrate
difference in progression of LV dysfunction between cell
ypes,5,15 but these trials did not use intramyocardial cell
elivery, which constitutes a more specific delivery method.16
owever, it is acknowledged that the marrow-derived cell a
254 The Journal of Thoracic and Cardiovascular Surgery ● Novopulations used in the different trials and our studies are
ot identical (although their source of derivation is the
ame), possibly allowing for differential cell function on
ransplantation.
Although other studies have observed MPC differentia-
ion into an endothelial phenotype within vessel walls of
ell-implanted hearts,7 this study demonstrated EPCs, but
ot MPCs, incorporating into vascular structures. The dif-
erentiation potential of cells might be altered by differences
n the severity of the pretreated infarct, the timing of cell
ransplantation, or both. The average baseline LVEF of
Figure 3. -Smooth muscle actin (-
SMA) staining. A-D, Representative im-
ages of -SMA staining in phosphate-
buffered saline (PBS)–treated (A), mes-
enchymal progenitor cell (MPC)–
treated (B), endothelial progenitor
cell (EPC)–treated (C), and MPC/EPC-
treated (D) hearts. Arrows indicate
positive -SMA staining in arterioles
(note the many arterioles observed in
EPC-treated hearts [C]), which was ex-
cluded from the calculation of myofi-
broblast density. E, The area of -SMA
staining (percentage of total area) rep-
resenting myofibroblast density for the
4 treatment groups after transplanta-
tion. *P < .05 versus PBS; †P < .05
versus all other treatments. Scale
bar  150 m.nimals in our study was 68%, with cell injection performed
ember 2007
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ETt 3 weeks after ligation. Many studies previously excluded
nimals with LVEFs of greater than 45%, and consequently,
he regenerating environments might have differently af-
ected the milieu in which the transplanted cells differenti-
te. Although MPCs did not demonstrate endothelial differ-
ntiation, these cells were observed to express troponin T,
hich is indicative of cardiomyocyte differentiation. How-
ver, the scope of this study did not assess the possibility
hat MPC expression of troponin T might have been the
esult of transdifferentiation or cell fusion, as previously
eported.24 A limitation of the cell-labeling procedures used
n this study is the possibility of false-positive identification
rom the loss of the label from the transplanted cells and
ptake by host cells. However, this would not affect the
ascular density or functional measurements, which were
ot dependent on cell identification but rather on the overall
ffect of the treatment.
As a consequence of the outlined cell-identification is-
ues, a limitation of this study is that the level of engraft- m
The Journal of Thoracicent of donor cells between treatments was not compared.
t is possible that greater loss of one cell type versus the
ther was in part responsible for the observed differences
n cardioprotective effect. It has been demonstrated pre-
iously that low cell survival can minimize the functional
ontribution of nonangiogenic cell populations.20,25 But
ell loss is a universal phenomenon of cell transplanta-
ion,25 and the numbers of cells transplanted in the
resent study were similar to that used in other EPC and
PC model studies.2,7,8 The cells in the present study
ere given equal opportunity to achieve a therapeutic
esponse in equal environmental conditions. However,
he environment might not be ideal for either cell type,
nd customized manipulation of the experimental condi-
ions, such as angiogenic cotransfection or pretreat-
ent,20,25 could improve the response to treatment with
ither cell type.
Similarly, improvements in functional parameters of the
Figure 4. Connexin43 staining. A and B,
Examples of connexin43 staining in bor-
der zone cardiomyocytes in phosphate-
buffered saline (PBS)–treated (A) and en-
dothelial progenitor cell (EPC)–treated
(B) hearts. Scale bar  50 m. C, Intra-
cellular connexin43 per myocyte in the
infarct and peri-infarct areas for the 4
treatment groups. *P < .05 versus the
PBS group. MPC, Mesenchymal progen-
itor cell.yocardium after various cell therapies have been widely
and Cardiovascular Surgery ● Volume 134, Number 5 1255
rr
a
c
F
t
r
p
p
o
o
t
c
c
d
p
H
E
t
T
Evolving Technology Suuronen et al
1
ETeported.26 In our infarct model, however, further deterio-
ation was encountered in all except the EPC group. This
dds to other recent evidence casting doubt on the true effi-
acy of MPC treatments in regenerating the myocardium.27
urthermore, and as reviewed by Murry and colleagues,28
he benefit of a surprisingly wide range of cell types might
esult from improvement of the infarct’s passive mechanical
roperties, amelioration of ventricular remodeling, and/or
aracrine effects. In support of this, the present study dem-
nstrated equivalent connexin43 density in cardiomyocytes
f all cell-treated hearts, which was significantly greater i
256 The Journal of Thoracic and Cardiovascular Surgery ● Novhan that of PBS-treated control hearts. Through a para-
rine mechanism, the transplanted cells potentially in-
reased connexin43 expression, as has been previously
emonstrated.29
It might be premature to conclude that the EPC is a superior
rogenitor cell for cell-based myocardial restoration therapy.
owever, the present data demonstrated that transplanted
PCs enhance vasculogenesis compared with MPCs and that
his was coupled with halted progression of LV dysfunction.
his suggests that angiogenesis is an important mechanism for
Figure 5. Vascular density. Representa-
tive-smooth muscle actin–stained sec-
tions of infarct border zone territories
showing the positively stained smooth
muscle cells of arterioles in hearts that
received phosphate-buffered saline (PBS;
A), mesenchymal progenitor cell (MPC;
B), endothelial progenitor cell (EPC; C),
or MPC/EPC (D) treatment. Scale bar
200 m. E, The number of arterioles
(per square millimeter) in the infarct
and border zone for the 4 treatment
groups. *P < .01 versus all other
groups within territory (infarct or bor-
der zone); #P < .05 versus PBS-treated
hearts.nfarct functional recovery in cell-based therapy. Until myo-
ember 2007
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ETardial syncytia–forming cell-based strategies are developed
nd functionally demonstrated, focusing on the transplantation
f primarily vasculogenic cells, such as the EPC, might be an
qually viable or even superior cell-based approach for the
reatment of MI.
We thank Monir Ahmad, Stephanie Dean, Wendy Prichett-
ejic, and Rick Seymour for technical assistance.
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